WO2001078698A2 - Use of ngf-antagonists for the prevention or treatment of chronic visceral pain - Google Patents

Use of ngf-antagonists for the prevention or treatment of chronic visceral pain Download PDF

Info

Publication number
WO2001078698A2
WO2001078698A2 PCT/EP2001/003490 EP0103490W WO0178698A2 WO 2001078698 A2 WO2001078698 A2 WO 2001078698A2 EP 0103490 W EP0103490 W EP 0103490W WO 0178698 A2 WO0178698 A2 WO 0178698A2
Authority
WO
WIPO (PCT)
Prior art keywords
ngf
growth factor
nerve growth
antagonist
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/003490
Other languages
French (fr)
Other versions
WO2001078698A3 (en
Inventor
Laurent Diop
Laure Delafoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to EP01927818A priority Critical patent/EP1282421A2/en
Priority to AU2001254746A priority patent/AU2001254746A1/en
Priority to BR0110028-9A priority patent/BR0110028A/en
Priority to CA002404117A priority patent/CA2404117A1/en
Priority to JP2001575999A priority patent/JP2003530427A/en
Priority to MXPA02009654A priority patent/MXPA02009654A/en
Publication of WO2001078698A2 publication Critical patent/WO2001078698A2/en
Publication of WO2001078698A3 publication Critical patent/WO2001078698A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention relates to the use of NGF antagonists for the prevention or treatment of chronic visceral pain, such as chronic visceral pain due to a physiological disorder, for example dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia or irritable bowel syndrome.
  • chronic visceral pain such as chronic visceral pain due to a physiological disorder, for example dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia or irritable bowel syndrome.
  • nonsteroidal anti-inflammatory therapeutic compounds which are used to treat mild pain, but whose therapeutic use in the visceral sphere is limited by undesirable gastrointestinal effects such as gastric erosion, the formation of peptic ulcer or the inflammation of the duodenum and of the colon;
  • chronic pain and particularly chronic visceral pain.
  • the neurological mechanisms of visceral pain differ from those involved in somatic pain and thus the available experimental results concerning somatic pain cannot be extrapolated a priori to visceral pain.
  • the perception of visceral pain by the patient and the psychological process to which they are subjected differ from those encountered in the case of somatic pain.
  • the candidate therapeutic compounds suggested are in particular the following compounds: (1) 5-HT antagonists which inhibit the binding of serotonin to the 5-HT-type receptors.
  • Hypothalamic factors such as analogues of somatostatin or analogues of gonadotrophin-releasing hormone. Few medicaments are therefore known to act selectively on the hypersensitivity linked to gastrointestinal disorders (FARTHING M.J., 1998, Drugs, vol. 56: 11-21).
  • the inventors focused on finding compounds capable of bringing relief to the patient suffering from chronic visceral pain and therefore of acting on at least one of the targets physiologically involved in the manifestation of these types of chronic visceral pain, which targets were unknown before the invention.
  • One aspect of the invention consists in using the capacity of NGF- antagonists to bring relief to the patient suffering from chronic visceral pain.
  • nerve growth factor (NGF) antagonists were capable of inhibiting or blocking the visceral hypersensitivity present in the pathophysiology of visceral functional disorders, in the case of chronic pain.
  • chronic visceral functional disorders is understood to mean disorders of the sensitivity of the viscera having a nervous origin, also known by the name visceralgia.
  • the viscera include the digestive, respiratory and urogenital organs and the endocrine systems, as well as the spleen, the heart and the large vessels.
  • a chronic visceralgia is characterized by a threshold of sensitivity to pain which is lowered compared with the normal threshold, in response to external mechanical stimuli.
  • Chronic visceral pain is in addition characterized by the absence of an inflammatory situation concomitant with the functional disorders.
  • chronic visceral pain includes the following chronic disorders:
  • pancreatitis which is characterized by rapid loss of weight, asthenia, pain at the pancreatic point, a jaundice with distension of the gall bladder and digestive disorders due to pancreatic insufficiency, including hereditary chronic pancreatitis, a dominant autosomally transmitted disease which manifests itself from childhood by abdominal and recidivous painful attacks and which is characterized in adults by signs of insufficiency as well as by calcifications of the pancreas;
  • IBS irritable bowel syndrome
  • the criteria for the diagnosis of IBS are (1) abdominal pain or discomfort which is relieved by defecation and which is associated with a modification of the frequency and of the consistency of the stools and (2) an irregular defecation profile characterized by at least three of the following phenomena: (a) frequency of the stools affected, (b) form of the stools altered, (c) passing of the stool affected, (d) passing of mucus, and (e) sensation of abdominal distension.
  • Chronic visceral pain in particular gastrointestinal pain, is characterized by an abnormal perception of various external stimuli in the patients or in the animal.
  • This abnormal perception of external stimuli may be defined as a decrease in the sensitivity threshold of the patient or of the animal to these external stimuli, compared with a control subject.
  • allodynia This physiopathological condition in which a stimulus which is not painful under normal conditions is perceived as being painful and which corresponds to a decrease in the sensitivity threshold is called allodynia.
  • NGF nerve growth factor
  • the subject of the present invention is therefore in particular the use of a nerve growth factor (NGF) antagonist for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pain.
  • NGF nerve growth factor
  • the invention relates in particular to the use of a nerve growth factor (NGF) antagonist which is binds to the said nerve growth factor.
  • NGF nerve growth factor
  • the invention preferably relates to the use of a nerve growth factor (NGF) antagonist which is an antibody which binds specifically to the nerve growth factor (NGF).
  • NGF nerve growth factor
  • the invention also relates to the use of a nerve growth factor (NGF) antagonist which binds to the Tyrosine kinase A nerve growth factor receptor.
  • NGF nerve growth factor
  • the invention also consists in the use of a nerve growth factor (NGF) antagonist which binds either to NGF, or to the Tyrosine kinase A NGF receptor for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pain due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome.
  • a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome.
  • Another aspect of the invention is a pharmaceutical composition for the prevention or treatment of chronic visceral pain, characterized in that it comprises a pharmaceutically effective quantity of a nerve growth factor (NGF) antagonist, in combination with one or more pharmaceutically acceptable excipients.
  • NGF nerve growth factor
  • a pharmaceutical composition according to the invention contains in particular a nerve growth factor (NGF) antagonist which binds to the said nerve growth factor.
  • NGF nerve growth factor
  • a pharmaceutical composition according to the invention preferably contains a nerve growth factor (NGF) antagonist which is an antibody which specifically binds to the nerve growth factor (NGF).
  • NGF nerve growth factor
  • Another pharmaceutical composition according to the invention contains a nerve growth factor (NGF) antagonist which binds to the Tyrosine kinase A which is an nerve growth factor receptor.
  • NGF nerve growth factor
  • a pharmaceutical composition according to the invention is characterised in that it is intended for the prevention or treatment of chronic visceral pain due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome.
  • a pharmaceutical composition according to the invention is formulated for oral administration.
  • Figure 1 illustrates the effect of NGF injected intraperitoneally at various doses on the colonic pain threshold.
  • the results are expressed as the mean plus or minus the standard error of the mean (SEM) of the pressure values.
  • SEM standard error of the mean
  • the test carried out is a two-sided Student's T test, of the unequal variance type with 2 examples, ns means not statistically significant, ** means p less than 0.01 and *** means p less than 0.001 versus control threshold.
  • Figure 2 illustrates the effect of an anti-NGF antibody and an anti- TGF ⁇ antibody, used as control antibody, on the colonic pain threshold in rats treated beforehand with TNBS (trinitrobenzenesulphonic acid).
  • the results are expressed as the mean plus or minus the standard error of the mean (SEM) of the pressure values measured.
  • SEM standard error of the mean
  • the test carried out is a two-sided Student's T test, of the unequal variance type with 2 examples.
  • *** means p less than 0.001 versus threshold of TNBS -treated rats receiving vehicle.
  • Figure 3 illustrates the effect of ALE-0540 an NGF receptor antagonist on the colonic pain threshold in rats treated beforehand with TNBS (trinitrobenzenesulphonic acid). The results are expressed as the mean plus or minus the standard error of the mean (SEM) of the pressure values measured. The test carried out is a two-sided Student's T test, of the unequal variance type with 2 examples. ** means p less than 0.01, versus threshold of TNBS-treated rats receiving the ALE-0540 vehicle.
  • NGF antagonist is understood to mean a compound capable of inhibiting the binding of nerve growth factor (NGF) to its receptor, Tyrosine kmase A (TrkA) That is to say a)
  • the NGF antagonists according to the invention include compounds capable of specifically binding to NGF and of thus preventing its binding to the TrkA receptor b) Also forming part of the NGF-antagomsts for the purposes of the invention, are the compounds capable of specifically binding to the TrkA receptor for NGF, thereby preventing the binding of NGF to its receptor
  • a first group of antagonist compounds comprises antibodies which specifically bind either to the nerve growth factor (NGF), or to the TrkA receptor, such as those descnbed in application PCT No WO 97/21732, whose teaching is incorporated by reference into the present descnption
  • this antibody will be preferably administered at the rate of 1 to 10 ⁇ g/kg of the weight of the patient per dose administered
  • This treatment of chronic visceral pam requires in general several successive administrations of the antibody, for example over time intervals ranging from one to four weeks
  • antibody' includes polyclonal and monoclonal antibodies, as well as antibody fractions, for example F(ab)' or Fab, single chain antibody fragments (ScFv), chimeric antibodies or humanized antibodies.
  • a second group of antagonists of the invention comprises synthetic molecules.
  • NGF nerve growth factor
  • the NGF-antagonists may also be compounds binding to the TrkA receptor for NGF.
  • the NGF-antagonists used according to the invention comprise solvates, hydrates and any pharmaceutically acceptable salts of such compounds.
  • the pharmaceutically acceptable salts of an NGF-antagonist which are used according to the invention comprise acetate, benzenesulphonate, benzoate, bitartrate, acetate of calcium, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloyl arsanilate, hexyl resorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogen carbonate, as well as the other salts described in the review by BERGE et al.
  • a pharmaceutical composition according to the invention is advantageously produced by formulating the NGF-antagomst in a dosage form comprising at least one pharmaceutically acceptable excipient or vehicle
  • the pharmaceutically acceptable vehicles may be either solids or liquids
  • a pharmaceutical composition according to the invention is characterized in that it is a formulation for oral administration
  • Solid dosage forms for oral administration include gelatin capsules, tablets, pills, powders and granules
  • the nerve growth factor (NGF) antagonist is used for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pam due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and IBS
  • the subject of the invention is also a pharmaceutical composition for the prevention or treatment of chrome visceral pam, charactenzed in that it compnses a pharmaceutically effective quantity of a nerve growth factor (NGF) antagonist, where appropnate in combination with one or more pharmaceutically acceptable excipients
  • NGF nerve growth factor
  • a nerve growth factor antagonist is understood to mean, according to the invention, a quantity of the said antagonist compound which is capable of abolishing, in the subject considered, the decrease in the sensitivity threshold to external stimuli with a return of this sensitivity threshold to a level comparable to that observed in healthy subjects.
  • a compound described as an antagonist of neurotrophins in publication PCT No. WO 98/17278 will be advantageously used in quantities allowing it to reach a concentration in the spinal fluid of between 1 and 500 ⁇ M.
  • an NGF-antagonist according to the invention will be administered at the rate of 0.1 to 300 mg/kg of the weight of the patient divided into one to three doses.
  • doses ranging from 5 to 500 mg per dose will be preferably administered.
  • Distension studies were carried out on waking rats in isobaric mode, using pressure increments of 5 mm of mercury every thirty seconds.
  • a latex balloon, placed in the distal part of the colon is linked to an electronic barostat.
  • the pain threshold is defined as the pressure inducing the first abdominal contraction.
  • Each rat is subjected to four distension trials so as to increase the reproducibility of the test.
  • the mean of the pressure values is calculated on the thresholds observed for the four successive distensions.
  • a laparotomy is carried out on rats anaesthetized with acepromazine (12 mg/kg i.p.) and ketamine (80 mg/kg i.p.) so as to inject into the proximal colon the trinitrobenzenesulphonic acid (TNBS) (50 mg/kg) in ethanol at 30%.
  • the rats are then placed in individual cages.
  • the colonic distension experiment is performed seven days after the administration of TNBS.
  • S-NGF obtained from mouse submaxillary gland (marketed by the company SIGMA under the reference N-6009) is dissolved in 0.1% bovine serum albumin (BSA).
  • BSA bovine serum albumin
  • 0.1 ng to 100 ng of NGF are injected by the i.p. route, 30 minutes before the distension.
  • the anti-NGF antibody marketed by the company SIGMA under the reference N-6655 is a fractionated rabbit antiserum directed against 2.5 S-NGF.
  • the anti-NGF antibody at the dilution of 1/2000 in sterile water, was injected by the i.p. route in a volume of 1 to 2 ml/kg, 30 minutes before the distension experiment.
  • the anti-TGF ⁇ antibody (Anti-Pan Transforming growth factor) is the IgG fraction of an antiserum directed against the human TGF ⁇ obtained in rabbits, marketed by the company SIGMA under the reference T-9429.
  • the anti- TGF ⁇ antibody at a concentration of 9 ⁇ g/ml in sterile water was injected by the i.p. route in a volume of 2 ml/kg, 30 minutes before the distension experiment.
  • the structure of the ALE-0540 compound is the following:
  • the NGF receptor antagonist, ALE-0540 at doses of 10 to 30 mg/kg was injected by the subcutaneous route in a volume of 2 ml/kg in cyclodextrin (20%, the ALE-0540 vehicle) in TNBS-treated rats, 30 minutes before the distension experiment.
  • Na ⁇ ve rats were subjected to distension experiments with a balloon placed in the distal part of the colon. This is gradually inflated until an abdominal muscle reflex reaction is observed which reflects the onset of pain. The pressure applied to the balloon at the time of the abdominal muscle reflex determines the value of the colonic pain threshold.
  • the rats receive by the i.p. route either bovine serum albumin alone, or a solution of serum albumin containing 0.1 ng to 100 ng of NGF.
  • the colonic pain threshold corresponds to a pressure of about 44 m Hg (empty bar, to the left of Figure 1).
  • Example 2 Effect of an anti-NGF antibody on the colonic distension-induced pain threshold in TNBS-treated rats
  • the induction of chronic allodynia in the colon was obtained by injecting TNBS into rats, seven days before the distension experiment, as indicated in the section Materials and Methods.
  • the level of activity of myeloperoxidase in the proximal colon collected from rats seven days after injection of TNBS made it possible to observe levels of myeloperoxidase activity of about 30 U/mg of proteins, whereas a level of activity of about 130 U/mg of proteins had been observed in proximal colon three days after the injection.
  • myeloperoxidase activity in the distal colon of TNBS-treated rats, three or seven days after the injection is not significantly different from myeloperoxidase activity in the distal colon of saline-treated rats.
  • 1 U is the quantity of enzyme which determines an increase in the absorbence at 470 nm of 1.0 per minute at pH 7.0 and at 25°C, calculated relative to the initial rate with guaiacol as substrate.
  • the technique for measuring the myeloperoxidase activity used is that described by GRISHAM et al. (1990, Methods in enzymology, vol. 186: 729-742).
  • the bars represent respectively from left to right: (a) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS;
  • the colonic pain threshold in rats treated with TNBS is greatly reduced (about 17 mmHg) relative to the control rats (about 44 mmHg).
  • anti-NGF antibody 2 ml/kg at the dilution of
  • NGF antibody used in these experiments is capable of bringing the threshold of pain in the colon to a level comparable to that found in the control rats in which no chronic allodynia of the colon had been induced.
  • Example 3 Effect of ALE-0540, an NGF receptor antagonist, on TNBS- induced colonic allodynia in response to distension
  • ALE-0540 is a nonpeptidic nerve growth factor receptor antagonist.
  • the induction of chronic allodynia in the colon was obtained by injecting TNBS into rats, seven days before the distension experiment, as indicated in the section Materials and Methods.
  • the control is the threshold value of pain in naive rats which is of about 44 mm ofHg.
  • the bars represent respectively from left to right:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of a nerve growth factor (NGF) antagonist for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pain and corresponding pharmaceutical compositions.

Description

USE OF NGF-ANT AGONISTS FOR THE PREVENTION OR TREATMENT OF CHRONIC VISCERAL PAIN
Field of the invention
The present invention relates to the use of NGF antagonists for the prevention or treatment of chronic visceral pain, such as chronic visceral pain due to a physiological disorder, for example dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia or irritable bowel syndrome.
Technological background
There are two general categories of medicaments for the treatment of pain, both of which have disadvantages:
(1) nonsteroidal anti-inflammatory therapeutic compounds which are used to treat mild pain, but whose therapeutic use in the visceral sphere is limited by undesirable gastrointestinal effects such as gastric erosion, the formation of peptic ulcer or the inflammation of the duodenum and of the colon;
(2) morphine and related opioids, which are used to treat moderate to severe pain but whose therapeutic use is limited because of undesirable effects such as constipation, respiratory depression and the risk of addiction.
A need therefore exists for identifying compounds capable of bringing relief, with no side effects, to the patient suffering from chronic pain, and particularly chronic visceral pain. Although the precise mechanisms for visceral pain differ depending on the organs and organ systems, two principles commonly apply to all types of visceral pain.
According to a first principle, the neurological mechanisms of visceral pain differ from those involved in somatic pain and thus the available experimental results concerning somatic pain cannot be extrapolated a priori to visceral pain.
According to a second principle, the perception of visceral pain by the patient and the psychological process to which they are subjected differ from those encountered in the case of somatic pain.
Among the types of visceral pain, it is possible to distinguish acute visceral pain and chronic visceral pain. In general, acute visceral pain is associated with an inflammatory situation and is in fact likened by persons skilled in the art to so-called inflammatory pain. The study of the physiology of acute visceral pain is thus carried out in an experimentally induced inflammatory situation.
It emerges from the above observations that the mechanisms involved in different physiopathological situations, such as acute visceral pain and chronic visceral pain, although unknown up until now, are distinct. This is in addition confirmed by the fact that the classes of candidate therapeutic compounds for treating either type, acute or chronic, of visceral pain are different.
In the case of chronic visceral pain, the candidate therapeutic compounds suggested are in particular the following compounds: (1) 5-HT antagonists which inhibit the binding of serotonin to the 5-HT-type receptors.
(2) Cholecystokin (CCK) antagonists.
(3) Opioid substances.
(4) Hypothalamic factors, such as analogues of somatostatin or analogues of gonadotrophin-releasing hormone. Few medicaments are therefore known to act selectively on the hypersensitivity linked to gastrointestinal disorders (FARTHING M.J., 1998, Drugs, vol. 56: 11-21).
Summary of the invention
The inventors focused on finding compounds capable of bringing relief to the patient suffering from chronic visceral pain and therefore of acting on at least one of the targets physiologically involved in the manifestation of these types of chronic visceral pain, which targets were unknown before the invention.
One aspect of the invention consists in using the capacity of NGF- antagonists to bring relief to the patient suffering from chronic visceral pain.
It has been shown, in accordance with the invention, that nerve growth factor (NGF) antagonists were capable of inhibiting or blocking the visceral hypersensitivity present in the pathophysiology of visceral functional disorders, in the case of chronic pain.
According to the invention, the expression chronic visceral functional disorders is understood to mean disorders of the sensitivity of the viscera having a nervous origin, also known by the name visceralgia. The viscera include the digestive, respiratory and urogenital organs and the endocrine systems, as well as the spleen, the heart and the large vessels.
From the medical point of view, a chronic visceralgia is characterized by a threshold of sensitivity to pain which is lowered compared with the normal threshold, in response to external mechanical stimuli. Chronic visceral pain is in addition characterized by the absence of an inflammatory situation concomitant with the functional disorders.
For the purposes of the invention, chronic visceral pain includes the following chronic disorders:
- chronic dyspepsia, a functional digestion disorder occurring in the absence of a detectable organic lesion and which may be symptomatic of other diseases or other disorders;
- chronic dysmenorrhoea, characterized by pain associated with menstruation;
- chronic pancreatitis, which is characterized by rapid loss of weight, asthenia, pain at the pancreatic point, a jaundice with distension of the gall bladder and digestive disorders due to pancreatic insufficiency, including hereditary chronic pancreatitis, a dominant autosomally transmitted disease which manifests itself from childhood by abdominal and recidivous painful attacks and which is characterized in adults by signs of insufficiency as well as by calcifications of the pancreas;
- chronic gastrooesophageal reflux, which is characterized by a return into the oesophagus of the acidic gastric content and which causes. generally after a meal, ascending retrosternal burns, sometimes accompanied by acidic regurgitations;
- IBS (irritable bowel syndrome), which is a non-inflammatory chronic disease characterized by abdominal pain and diarrhoea and/or constipation, with no detectable biochemical and histological modification. The criteria for the diagnosis of IBS are (1) abdominal pain or discomfort which is relieved by defecation and which is associated with a modification of the frequency and of the consistency of the stools and (2) an irregular defecation profile characterized by at least three of the following phenomena: (a) frequency of the stools affected, (b) form of the stools altered, (c) passing of the stool affected, (d) passing of mucus, and (e) sensation of abdominal distension.
Chronic visceral pain, in particular gastrointestinal pain, is characterized by an abnormal perception of various external stimuli in the patients or in the animal. This abnormal perception of external stimuli may be defined as a decrease in the sensitivity threshold of the patient or of the animal to these external stimuli, compared with a control subject.
This physiopathological condition in which a stimulus which is not painful under normal conditions is perceived as being painful and which corresponds to a decrease in the sensitivity threshold is called allodynia.
It has thus been shown, according to the invention, that the administration of a nerve growth factor (NGF) antagonist to a subject suffering from chronic visceral pain made it possible to abolish the lowering of the sensitivity threshold of this subject to external stimuli, with a return to a sensitivity threshold comparable to that observed in a control healthy subject.
The subject of the present invention is therefore in particular the use of a nerve growth factor (NGF) antagonist for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pain.
The invention relates in particular to the use of a nerve growth factor (NGF) antagonist which is binds to the said nerve growth factor.
The invention preferably relates to the use of a nerve growth factor (NGF) antagonist which is an antibody which binds specifically to the nerve growth factor (NGF).
The invention also relates to the use of a nerve growth factor (NGF) antagonist which binds to the Tyrosine kinase A nerve growth factor receptor. The invention also consists in the use of a nerve growth factor (NGF) antagonist which binds either to NGF, or to the Tyrosine kinase A NGF receptor for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pain due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome.
Another aspect of the invention is a pharmaceutical composition for the prevention or treatment of chronic visceral pain, characterized in that it comprises a pharmaceutically effective quantity of a nerve growth factor (NGF) antagonist, in combination with one or more pharmaceutically acceptable excipients.
A pharmaceutical composition according to the invention contains in particular a nerve growth factor (NGF) antagonist which binds to the said nerve growth factor.
A pharmaceutical composition according to the invention preferably contains a nerve growth factor (NGF) antagonist which is an antibody which specifically binds to the nerve growth factor (NGF).
Another pharmaceutical composition according to the invention contains a nerve growth factor (NGF) antagonist which binds to the Tyrosine kinase A which is an nerve growth factor receptor.
A pharmaceutical composition according to the invention is characterised in that it is intended for the prevention or treatment of chronic visceral pain due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome. Preferably, a pharmaceutical composition according to the invention is formulated for oral administration.
Brief description of the figures
Figure 1 illustrates the effect of NGF injected intraperitoneally at various doses on the colonic pain threshold. The results are expressed as the mean plus or minus the standard error of the mean (SEM) of the pressure values. The test carried out is a two-sided Student's T test, of the unequal variance type with 2 examples, ns means not statistically significant, ** means p less than 0.01 and *** means p less than 0.001 versus control threshold.
Figure 2 illustrates the effect of an anti-NGF antibody and an anti- TGFβ antibody, used as control antibody, on the colonic pain threshold in rats treated beforehand with TNBS (trinitrobenzenesulphonic acid). The results are expressed as the mean plus or minus the standard error of the mean (SEM) of the pressure values measured. The test carried out is a two-sided Student's T test, of the unequal variance type with 2 examples. *** means p less than 0.001 versus threshold of TNBS -treated rats receiving vehicle.
Figure 3 illustrates the effect of ALE-0540 an NGF receptor antagonist on the colonic pain threshold in rats treated beforehand with TNBS (trinitrobenzenesulphonic acid). The results are expressed as the mean plus or minus the standard error of the mean (SEM) of the pressure values measured. The test carried out is a two-sided Student's T test, of the unequal variance type with 2 examples. ** means p less than 0.01, versus threshold of TNBS-treated rats receiving the ALE-0540 vehicle. Detailed description of the invention
The expression "NGF antagonist" is understood to mean a compound capable of inhibiting the binding of nerve growth factor (NGF) to its receptor, Tyrosine kmase A (TrkA) That is to say a) The NGF antagonists according to the invention include compounds capable of specifically binding to NGF and of thus preventing its binding to the TrkA receptor b) Also forming part of the NGF-antagomsts for the purposes of the invention, are the compounds capable of specifically binding to the TrkA receptor for NGF, thereby preventing the binding of NGF to its receptor
A first group of antagonist compounds comprises antibodies which specifically bind either to the nerve growth factor (NGF), or to the TrkA receptor, such as those descnbed in application PCT No WO 97/21732, whose teaching is incorporated by reference into the present descnption
In the case of an antibody specific for NGF, there may also be cited the punfied antι-2 5S-NGF antiserum marketed by the company Sigma Chemicals (USA), in particular under the reference N-6655
As regards the dose either of an antibody which specifically binds to NGF, or of an antibody which specifically binds to the TrkA receptor for NGF, this antibody will be preferably administered at the rate of 1 to 10 μg/kg of the weight of the patient per dose administered This treatment of chronic visceral pam requires in general several successive administrations of the antibody, for example over time intervals ranging from one to four weeks
The term patient is understood to mean a mammal and preferabl humans The term "antibody'" includes polyclonal and monoclonal antibodies, as well as antibody fractions, for example F(ab)' or Fab, single chain antibody fragments (ScFv), chimeric antibodies or humanized antibodies.
A second group of antagonists of the invention comprises synthetic molecules.
By way of example, there may be mentioned the antagonists of neurotrophin described in application PCT No. WO 98/17278, peptides derived from NGF with antagonist effect, such as those described in application PCT No. WO 89/09225 and bicyclic peptides which are antagonists of NGF such as those described in application PCT No. WO 97/15593. The teaching of the various patents cited above is incorporated by reference into the present description.
Among these synthetic molecules are nerve growth factor (NGF) antagonists constituting a pharmaceutical composition according to the invention, which are chosen from the compounds binding to the said nerve growth factor.
The NGF-antagonists may also be compounds binding to the TrkA receptor for NGF.
The NGF-antagonists used according to the invention comprise solvates, hydrates and any pharmaceutically acceptable salts of such compounds. The pharmaceutically acceptable salts of an NGF-antagonist which are used according to the invention comprise acetate, benzenesulphonate, benzoate, bitartrate, acetate of calcium, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloyl arsanilate, hexyl resorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogen carbonate, as well as the other salts described in the review by BERGE et al. (1977, J. Pharm. sci., vol. 66: 1-19). A pharmaceutical composition according to the invention is advantageously produced by formulating the NGF-antagomst in a dosage form comprising at least one pharmaceutically acceptable excipient or vehicle To prepare a pharmaceutical composition according to the invention, the pharmaceutically acceptable vehicles may be either solids or liquids
Preferably, a pharmaceutical composition according to the invention is characterized in that it is a formulation for oral administration
Solid dosage forms for oral administration include gelatin capsules, tablets, pills, powders and granules
In general, the pharmaceutically acceptable vehicles useful for the preparation of a composition for administration in vivo are in particular described in "REMINGTON'S Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pen , 1985".
Preferably, the nerve growth factor (NGF) antagonist is used for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pam due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and IBS
The subject of the invention is also a pharmaceutical composition for the prevention or treatment of chrome visceral pam, charactenzed in that it compnses a pharmaceutically effective quantity of a nerve growth factor (NGF) antagonist, where appropnate in combination with one or more pharmaceutically acceptable excipients
The expression "pharmaceutically effective quantity" of a nerve growth factor antagonist is understood to mean, according to the invention, a quantity of the said antagonist compound which is capable of abolishing, in the subject considered, the decrease in the sensitivity threshold to external stimuli with a return of this sensitivity threshold to a level comparable to that observed in healthy subjects.
By way of illustration, a compound described as an antagonist of neurotrophins in publication PCT No. WO 98/17278 will be advantageously used in quantities allowing it to reach a concentration in the spinal fluid of between 1 and 500 μM.
In general, when it is not an antibody, an NGF-antagonist according to the invention will be administered at the rate of 0.1 to 300 mg/kg of the weight of the patient divided into one to three doses.
For an adult patient of normal weight, doses ranging from 5 to 500 mg per dose will be preferably administered.
The invention is in addition illustrated, without being limited as a result, in the following figures and examples.
Examples:
A - Materials and methods:
A.l. Animals
Adult male rats of the Wistar strain, 320 to 350 g in weight (obtained from the Janvier farm, Le Genest-Saint-Isle, France) were used for all the experiments. They were kept under controlled conditions of temperature
(20 +/- 1°C), humidity (50 +/- 5%) and lighting (light from 7 to 19 hours). The animals were starved of food for 18 hours before the beginning of the experiments, the supply of water being maintained.
A.2. Behavioural study
Distension studies were carried out on waking rats in isobaric mode, using pressure increments of 5 mm of mercury every thirty seconds. A latex balloon, placed in the distal part of the colon is linked to an electronic barostat. The pain threshold is defined as the pressure inducing the first abdominal contraction. Each rat is subjected to four distension trials so as to increase the reproducibility of the test. The mean of the pressure values is calculated on the thresholds observed for the four successive distensions.
A.3. Administration of TNBS
A laparotomy is carried out on rats anaesthetized with acepromazine (12 mg/kg i.p.) and ketamine (80 mg/kg i.p.) so as to inject into the proximal colon the trinitrobenzenesulphonic acid (TNBS) (50 mg/kg) in ethanol at 30%. The rats are then placed in individual cages. The colonic distension experiment is performed seven days after the administration of TNBS.
A.4. Administration of NGF, of anti-NGF and anti-TGFβ antibodies
2.5 S-NGF obtained from mouse submaxillary gland (marketed by the company SIGMA under the reference N-6009) is dissolved in 0.1% bovine serum albumin (BSA). Into the naϊve rats, 0.1 ng to 100 ng of NGF are injected by the i.p. route, 30 minutes before the distension.
The anti-NGF antibody marketed by the company SIGMA under the reference N-6655 is a fractionated rabbit antiserum directed against 2.5 S-NGF.
The anti-NGF antibody, at the dilution of 1/2000 in sterile water, was injected by the i.p. route in a volume of 1 to 2 ml/kg, 30 minutes before the distension experiment.
The anti-TGFβ antibody (Anti-Pan Transforming growth factor) is the IgG fraction of an antiserum directed against the human TGFβ obtained in rabbits, marketed by the company SIGMA under the reference T-9429. The anti- TGFβ antibody, at a concentration of 9 μg/ml in sterile water was injected by the i.p. route in a volume of 2 ml/kg, 30 minutes before the distension experiment.
A.5. Administration of the NGF receptor antagonist ALE-0540
The structure of the ALE-0540 compound is the following:
Figure imgf000015_0001
The NGF receptor antagonist, ALE-0540, at doses of 10 to 30 mg/kg was injected by the subcutaneous route in a volume of 2 ml/kg in cyclodextrin (20%, the ALE-0540 vehicle) in TNBS-treated rats, 30 minutes before the distension experiment.
B. Results
Example 1: Effect of NGF on the colonic distension-induced pain threshold
Naϊve rats were subjected to distension experiments with a balloon placed in the distal part of the colon. This is gradually inflated until an abdominal muscle reflex reaction is observed which reflects the onset of pain. The pressure applied to the balloon at the time of the abdominal muscle reflex determines the value of the colonic pain threshold.
The rats receive by the i.p. route either bovine serum albumin alone, or a solution of serum albumin containing 0.1 ng to 100 ng of NGF.
The results are represented in Figure 1.
For the control rats which received only the bovine serum albumin, the colonic pain threshold corresponds to a pressure of about 44 m Hg (empty bar, to the left of Figure 1).
It is possible to observe that increasing doses of NGF (0.1 ng to 100 ng) induce a significant reduction in the threshold of pain in the colon in the naϊve rats (filled bars). Thus, the colonic pain threshold is lowered to less than 20 mmHg for 1 ng of NGF.
The experimental results of Example 1 therefore show that exogenous NGF induces visceral pain. Example 2: Effect of an anti-NGF antibody on the colonic distension-induced pain threshold in TNBS-treated rats
The induction of chronic allodynia in the colon was obtained by injecting TNBS into rats, seven days before the distension experiment, as indicated in the section Materials and Methods.
It was experimentally verified that no inflammatory- type situation is observed in the rats subjected to the experiment.
In particular, the level of activity of myeloperoxidase in the proximal colon collected from rats seven days after injection of TNBS made it possible to observe levels of myeloperoxidase activity of about 30 U/mg of proteins, whereas a level of activity of about 130 U/mg of proteins had been observed in proximal colon three days after the injection. Moreover, myeloperoxidase activity in the distal colon of TNBS-treated rats, three or seven days after the injection is not significantly different from myeloperoxidase activity in the distal colon of saline-treated rats. 1 U is the quantity of enzyme which determines an increase in the absorbence at 470 nm of 1.0 per minute at pH 7.0 and at 25°C, calculated relative to the initial rate with guaiacol as substrate.
The technique for measuring the myeloperoxidase activity used is that described by GRISHAM et al. (1990, Methods in enzymology, vol. 186: 729-742).
The results are presented in Figure 2. The control value for the threshold of sensitivity to pain in naϊve rats is represented in the form of a line at about 44 mm of Hg.
The bars represent respectively from left to right: (a) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS;
(b) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS, to which the anti-TGFβ antibody has been administered.
(c) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS, to which the anti-NGF antibody has been administered;
The colonic pain threshold in rats treated with TNBS is greatly reduced (about 17 mmHg) relative to the control rats (about 44 mmHg).
The administration of anti-NGF antibody ( 2 ml/kg at the dilution of
1/2000) reverses the effect of TNBS on the colonic pain threshold. Indeed, a pain threshold of 37.7 +/- 1.7 mmHg is obtained in the rats receiving the anti-NGF antibody against 16.9 +/- 1.5 mmHg for the rats treated with the vehicle. A p of less than 0.001 versus threshold of TNBS- and vehicle-treated rats was obtained by the Student's T test.
On the other hand, no modification in the colonic pain threshold is observed in TNBS-treated rats to which anti-TGFβ antibody has been administered. This example clearly shows that an NGF-antagonist, such as the anti-
NGF antibody used in these experiments, is capable of bringing the threshold of pain in the colon to a level comparable to that found in the control rats in which no chronic allodynia of the colon had been induced. These results show that the action of NGF on the visceral sensory nerves contributes to the development of visceral hypersensitivity and that an NGF-antagonist is therapeutically effective in this type of specific digestive disorder and more generally in chronic visceral pain.
Example 3: Effect of ALE-0540, an NGF receptor antagonist, on TNBS- induced colonic allodynia in response to distension
ALE-0540 is a nonpeptidic nerve growth factor receptor antagonist.
The induction of chronic allodynia in the colon was obtained by injecting TNBS into rats, seven days before the distension experiment, as indicated in the section Materials and Methods.
The results are presented in figure 3.
The control is the threshold value of pain in naive rats which is of about 44 mm ofHg.
The bars represent respectively from left to right:
(a) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS;
(b) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS, to which 10 mg/kg of ALE-0540, an NGF receptor antagonist has been administered;
(c) the mean value of the threshold of pain (+/- SEM) in rats treated with TNBS, to which 30 mg/kg of ALE-0540, an NGF receptor antagonist has been administered. 30 mg/kg ALE-0540 reverses the TNBS-induced colonic allodynia. Indeed, a colonic pain threshold of 37.6 +/- 4.5 mmHg is obtained in the TNBS- treated rats receiving 30 mg/kg ALE-0540 against 17.8 +/- 1.8 mmHg for the TNBS-treated rats receiving only the ALE-0540 vehicle.
A p of less than 0.01 versus TNBS-treated rats receiving vehicle was obtained for the Student's T test.
Results are expressed as mean +/- SEM (n=7-8)
These results show that a non-peptidic NGF receptor antagonist exhibits antiallodynic activity in this model of visceral hypersensitivity.

Claims

Claims
1. Use of a nerve growth factor (NGF) antagonist for the manufacture of a medicament intended for the prevention or treatment of chronic visceral pain.
2. Use according to Claim 1, characterized in that the nerve growth factor (NGF) antagonist binds to the said nerve growth factor.
3. Use according to Claim 2, characterized in that the nerve growth factor (NGF) antagonist is an antibody which binds specifically to the nerve growth factor (NGF).
4. Use according to Claim 1, characterized in that the nerve growth factor (NGF) antagonist binds to the Tyrosine kinase A nerve growth factor receptor.
5. Use according to claim 1 wherein the NGF antagonist is ALE-0540.
6. Use according to one of Claims 1 to 5, characterized in that the medicament is intended for the prevention or treatment of chronic visceral pain due to a physiological disorder such as dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome.
7. Pharmaceutical composition for the prevention or treatment of chronic visceral pain, characterized in that it comprises a pharmaceutically effective quantity of a nerve growth factor (NGF) antagonizing compound, in combination with one or more pharmaceutically acceptable excipients.
8. Pharmaceutical composition according to Claim 7, characterized in that the nerve growth factor (NGF) antagonist binds to the said nerve growth factor.
9. Pharmaceutical composition according to Claim 8, characterized in that the nerve growth factor (NGF) antagonist is an antibody which binds specifically to the nerve growth factor (NGF).
10. Pharmaceutical composition according to Claim 7, characterized in that the nerve growth factor (NGF) antagonist binds to the Tyrosine kinase A which is a nerve growth factor receptor.
11. Pharmaceutical composition according to one of Claims 6 to 10, characterized in that it is formulated for oral administration.
12. Method for the prevention or treatment of chronic visceral pain which comprises administering to a patient in need thereof a pharmaceutically effective quantity of a nerve growth factor antagonist.
13. A method according to claim 12 wherein the nerve growth factor (NGF) antagonist binds to the said nerve growth factor.
14. A method according to claim 12 wherein the nerve growth factor (NGF) antagonist is an antibody which binds specifically to the nerve growth factor (NGF).
15. A method according to claim 12 wherein the nerve growth factor (NGF) antagonist binds to the Tyrosine kinase A nerve growth factor receptor.
16. A method according to claim 12 wherein the nerve growth factor (NGF) antagonist is ALE-0540.
17. A method according to claim 12 wherein the chronic visceral pain is due to a physiological disorder selected from dysmenorrhoea, dyspepsia, gastrooesophageal reflux, pancreatitis, visceralgia and irritable bowel syndrome.
PCT/EP2001/003490 2000-04-13 2001-03-26 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain Ceased WO2001078698A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01927818A EP1282421A2 (en) 2000-04-13 2001-03-26 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
AU2001254746A AU2001254746A1 (en) 2000-04-13 2001-03-26 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
BR0110028-9A BR0110028A (en) 2000-04-13 2001-03-26 Use of ngf antagonists for the prevention or treatment of chronic visceral pain
CA002404117A CA2404117A1 (en) 2000-04-13 2001-03-26 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
JP2001575999A JP2003530427A (en) 2000-04-13 2001-03-26 Use of an NGF antagonist for the prevention or treatment of chronic visceral pain
MXPA02009654A MXPA02009654A (en) 2000-04-13 2001-03-26 Use of ngf antagonists for the prevention or treatment of chronic visceral pain.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/04782 2000-04-13
FR0004782A FR2807660A1 (en) 2000-04-13 2000-04-13 Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
US10/269,285 US20040071701A1 (en) 2000-04-13 2002-10-11 Use of NGF-antagonists for the prevention or treatment of chronic visceral pain

Publications (2)

Publication Number Publication Date
WO2001078698A2 true WO2001078698A2 (en) 2001-10-25
WO2001078698A3 WO2001078698A3 (en) 2002-04-25

Family

ID=32737514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003490 Ceased WO2001078698A2 (en) 2000-04-13 2001-03-26 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain

Country Status (8)

Country Link
US (1) US20040071701A1 (en)
EP (1) EP1282421A2 (en)
JP (1) JP2003530427A (en)
AU (1) AU2001254746A1 (en)
BR (1) BR0110028A (en)
CA (1) CA2404117A1 (en)
FR (1) FR2807660A1 (en)
WO (1) WO2001078698A2 (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
WO2004014428A1 (en) * 2002-08-09 2004-02-19 Ajinomoto Co.,Inc. Remedy for intestinal diseases and visceral pain
WO2004026329A1 (en) * 2002-09-19 2004-04-01 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2005019266A3 (en) * 2003-07-15 2005-04-28 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2006504744A (en) * 2002-10-08 2006-02-09 ライナット ニューロサイエンス コーポレイション Methods for treating postoperative pain by administering a nerve growth factor antagonist and compositions containing the nerve growth factor antagonist
WO2004096122A3 (en) * 2002-10-08 2006-06-01 Rinat Neuroscience Corp Use of ngf antagonists and opioids for treating pain
WO2006110883A2 (en) 2005-04-11 2006-10-19 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2006131952A1 (en) 2005-06-07 2006-12-14 Lay Line Genomics S.P.A. Novel analgesic treatment with prolonged effect
US7425329B2 (en) 2004-04-07 2008-09-16 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2009023540A1 (en) 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2009054468A1 (en) 2007-10-24 2009-04-30 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2010029497A1 (en) * 2008-09-12 2010-03-18 Pfizer Limited Treatment of endometriosis
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
EP2263692A1 (en) 2002-12-24 2010-12-22 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
WO2011049758A1 (en) 2009-10-09 2011-04-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2011116090A1 (en) 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
US8246956B2 (en) 2003-12-24 2012-08-21 Abbott Research B.V. Humanized anti-nerve growth factor antibodies
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US8486401B2 (en) 1999-05-26 2013-07-16 Lay Line Genomics S.P.A. Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
WO2013183032A2 (en) 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
WO2015148373A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015148344A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Trka kinase inhibitors, compositions and methods thereof
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9315571B2 (en) 2005-01-24 2016-04-19 Elan Pharma International Limited Specific binding members for NGF
US9346788B2 (en) 2014-02-05 2016-05-24 VM Oncology, LLC TrkA receptor tyrosine kinase antagonists and uses thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9718782B2 (en) 2013-09-22 2017-08-01 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9751947B2 (en) 2008-02-04 2017-09-05 Lay Line Genomics S.P.A. Antibodies and derivatives thereof
US9896447B2 (en) 2013-09-22 2018-02-20 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9914736B2 (en) 2014-03-26 2018-03-13 Merck Sharp & Dohme Corp. TrKA kinase inhibitors, compositions and methods thereof
US10323086B2 (en) 2002-12-24 2019-06-18 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US10556900B2 (en) 2015-04-08 2020-02-11 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US10597448B2 (en) 2009-08-28 2020-03-24 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
WO2023212596A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
WO2024196744A1 (en) 2023-03-17 2024-09-26 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
AU2015318324A1 (en) 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008483A1 (en) * 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
WO1997015593A1 (en) * 1995-10-25 1997-05-01 Queen's University At Kingston Neurotrophin antagonists
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
AU728523C (en) * 1996-10-21 2001-08-09 Nps Pharmaceuticals, Inc. Neurotrophin antagonist compositions
IT1306704B1 (en) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486401B2 (en) 1999-05-26 2013-07-16 Lay Line Genomics S.P.A. Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
US7727527B2 (en) * 2001-05-30 2010-06-01 Genentech, Inc. Anti-NGF antibodies for the therapeutic treatments
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
WO2004014428A1 (en) * 2002-08-09 2004-02-19 Ajinomoto Co.,Inc. Remedy for intestinal diseases and visceral pain
US7371559B2 (en) 2002-09-19 2008-05-13 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004026329A1 (en) * 2002-09-19 2004-04-01 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US8124724B2 (en) 2002-09-19 2012-02-28 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US8513396B2 (en) 2002-09-19 2013-08-20 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
JP2006505255A (en) * 2002-09-19 2006-02-16 アムジエン・インコーポレーテツド Peptides and related molecules that modulate the activity of nerve growth factor
AU2003285864C1 (en) * 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
WO2004096122A3 (en) * 2002-10-08 2006-06-01 Rinat Neuroscience Corp Use of ngf antagonists and opioids for treating pain
EP1556083A4 (en) * 2002-10-08 2006-10-11 Rinat Neuroscience Corp Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
EP2100902B1 (en) 2002-10-08 2019-12-18 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an antagonist antibody against the nerve growth factor and an opioid analgesic, and compositions containing the same
CN1878794B (en) * 2002-10-08 2011-11-30 里纳特神经系统学公司 NGF antagonist and opioid analgesic use in pain treatment
JP2006504744A (en) * 2002-10-08 2006-02-09 ライナット ニューロサイエンス コーポレイション Methods for treating postoperative pain by administering a nerve growth factor antagonist and compositions containing the nerve growth factor antagonist
EP2100902A1 (en) 2002-10-08 2009-09-16 Rinat Neuroscience Corp. Methods for treating pain by administering an antagonist antibody against the nerve growth factor and an opioid analgesic, and compositions containing the same
AU2003285864B2 (en) * 2002-10-08 2009-10-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2263692A1 (en) 2002-12-24 2010-12-22 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US11008386B2 (en) 2002-12-24 2021-05-18 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
EP3539569A1 (en) 2002-12-24 2019-09-18 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using the same in treating pain associated with musculo-skeletal disorders
US10323086B2 (en) 2002-12-24 2019-06-18 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP2270048A2 (en) 2002-12-24 2011-01-05 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
EA030259B1 (en) * 2003-07-15 2018-07-31 Амджен Инк. HUMAN NEUTRALIZING ANTIBODIES TO THE NERVE GROWTH FACTOR (NGF) AS A SELECTIVE NGF METABOLIC INHIBITOR
HRP20060033B1 (en) * 2003-07-15 2014-02-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US7795413B2 (en) 2003-07-15 2010-09-14 Amgen, Inc. Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US9260514B2 (en) 2003-07-15 2016-02-16 Amgen Inc. Methods of treating conditions caused by increased expression of nerve growth factor (NGF) or increased sensitivity to NGF using anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
CN102358903B (en) * 2003-07-15 2017-04-26 安姆根有限公司 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
CN102408483A (en) * 2003-07-15 2012-04-11 安姆根有限公司 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US8198410B2 (en) 2003-07-15 2012-06-12 Amgen Inc. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
WO2005019266A3 (en) * 2003-07-15 2005-04-28 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EP2364728A1 (en) * 2003-07-15 2011-09-14 Amgen, Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
AU2010202177B2 (en) * 2003-07-15 2013-12-12 Amgen Inc. Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
CN1849138B (en) * 2003-07-15 2011-11-30 安姆根有限公司 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
EA013614B1 (en) * 2003-07-15 2010-06-30 Амджен Инк. ISOLATED ANTIBODY TO NERVES GROWTH FACTOR (NGF) AND METHODS OF ITS APPLICATION
US8106167B2 (en) 2003-07-15 2012-01-31 Amgen Inc. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US7601818B2 (en) 2003-07-15 2009-10-13 Amgen, Inc. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
CN102408483B (en) * 2003-07-15 2016-06-08 安姆根有限公司 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
JP2015110601A (en) * 2003-12-24 2015-06-18 アボット・１１０・ベーフェー Humanized anti-NGF antibody
US8246956B2 (en) 2003-12-24 2012-08-21 Abbott Research B.V. Humanized anti-nerve growth factor antibodies
US8877491B2 (en) 2003-12-24 2014-11-04 Abbvie Inc. Polynucleotides encoding humanized anti-NGF antibodies
US8257710B2 (en) 2003-12-24 2012-09-04 Abbott Research, B.V. Method for the treatment of pain with humanized anti-nerve growth factor antibodies
EP2206728A1 (en) 2004-04-07 2010-07-14 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonistic antibody
US7425329B2 (en) 2004-04-07 2008-09-16 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
RU2389509C2 (en) * 2004-04-07 2010-05-20 Ринат Ньюросайенс Корп. Methods for bone cancer related pain management by administration of nerve growth factor antagonist
EP3372614A1 (en) 2004-04-07 2018-09-12 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US9701746B2 (en) 2005-01-24 2017-07-11 Medimmune Limited Methods of treating neuropathic pain with specific binding members for NGF
US9315571B2 (en) 2005-01-24 2016-04-19 Elan Pharma International Limited Specific binding members for NGF
EP3272358A1 (en) 2005-04-11 2018-01-24 Rinat Neuroscience Corporation Methods for treating osteoarthitis pain by administering a nerve growth factor antagonist and compositions containing the same
EP2305711A2 (en) 2005-04-11 2011-04-06 Rinat Neuroscience Corp. Methods for treating osteoarthitis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2006110883A2 (en) 2005-04-11 2006-10-19 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2006131952A1 (en) 2005-06-07 2006-12-14 Lay Line Genomics S.P.A. Novel analgesic treatment with prolonged effect
EP2484380A1 (en) 2005-06-07 2012-08-08 Abbott Research B.V. Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
US9688749B2 (en) 2005-06-07 2017-06-27 Abbvie Inc. Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
WO2009023540A1 (en) 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
EP2572729A2 (en) 2007-08-10 2013-03-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2009054468A1 (en) 2007-10-24 2009-04-30 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US9751947B2 (en) 2008-02-04 2017-09-05 Lay Line Genomics S.P.A. Antibodies and derivatives thereof
WO2010029497A1 (en) * 2008-09-12 2010-03-18 Pfizer Limited Treatment of endometriosis
JP2016180005A (en) * 2008-12-08 2016-10-13 ムンディファーマ インターナショナル コーポレイション リミテッド Protein receptor tyrosine kinase inhibitor composition
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
US9447181B2 (en) 2009-05-04 2016-09-20 Abbvie Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US10597448B2 (en) 2009-08-28 2020-03-24 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide
EP3028717A1 (en) 2009-10-09 2016-06-08 Amgen, Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2011049758A1 (en) 2009-10-09 2011-04-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2011116090A1 (en) 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
US10093725B2 (en) 2010-08-19 2018-10-09 Zoetis Belgium S.A. Anti-NGF antibodies and their use
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
EP3333188A1 (en) 2010-08-19 2018-06-13 Zoetis Belgium S.A. Anti-ngf antibodies and their use
EP4056589A1 (en) 2010-08-19 2022-09-14 Zoetis Belgium S.A. Anti-ngf antibodies and their use
US10125192B2 (en) 2010-08-19 2018-11-13 Zoetis Belgium S.A. Caninized anti-NGF antibodies and their use
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
US9951126B2 (en) 2011-10-25 2018-04-24 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9951128B2 (en) 2012-06-06 2018-04-24 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2013183032A2 (en) 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
US9718782B2 (en) 2013-09-22 2017-08-01 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9896447B2 (en) 2013-09-22 2018-02-20 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9855265B2 (en) 2014-02-05 2018-01-02 VM Oncology, LLC. Methods for treating cancer with TrkA receptor tyrosine kinase antagonists
US9346788B2 (en) 2014-02-05 2016-05-24 VM Oncology, LLC TrkA receptor tyrosine kinase antagonists and uses thereof
WO2015148373A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9914736B2 (en) 2014-03-26 2018-03-13 Merck Sharp & Dohme Corp. TrKA kinase inhibitors, compositions and methods thereof
US9815846B2 (en) 2014-03-26 2017-11-14 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9862707B2 (en) 2014-03-26 2018-01-09 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9862716B2 (en) 2014-03-26 2018-01-09 Merck Sharp & Dohme Corp. TRKA kinase inhibitors, compositions and methods thereof
WO2015148344A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Trka kinase inhibitors, compositions and methods thereof
US10556900B2 (en) 2015-04-08 2020-02-11 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US12049509B2 (en) 2018-03-12 2024-07-30 Zoetis Services Llc Nucleic acids encoding a canine antibody which binds nerve growth factor and vectors and host cells thereof
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
US12049507B2 (en) 2018-03-12 2024-07-30 Zoetis Services Llc Felinized anti-NGF antibodies and methods of treating pain
US12049508B2 (en) 2018-03-12 2024-07-30 Zoetis Services Llc Canine anti-NGF antibodies and methods of treating pain thereof
US12084506B2 (en) 2018-03-12 2024-09-10 Zoetis Services Llc Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies
US12084507B2 (en) 2018-03-12 2024-09-10 Zoetis Services Llc Humanized anti-NGF antibodies and methods of treating pain thereof
US12497459B2 (en) 2018-03-12 2025-12-16 Zoetis Services Llc Nucleic acids encoding canine anti-NGF antibodies and methods thereof
US12552871B2 (en) 2018-03-12 2026-02-17 Zoetis Services Llc Nucleic acids encoding humanized anti-NGF antibodies
WO2023212596A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
WO2024196744A1 (en) 2023-03-17 2024-09-26 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)

Also Published As

Publication number Publication date
JP2003530427A (en) 2003-10-14
CA2404117A1 (en) 2001-10-25
BR0110028A (en) 2003-06-03
AU2001254746A1 (en) 2001-10-30
WO2001078698A3 (en) 2002-04-25
FR2807660A1 (en) 2001-10-19
EP1282421A2 (en) 2003-02-12
US20040071701A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
US20040071701A1 (en) Use of NGF-antagonists for the prevention or treatment of chronic visceral pain
CN1723039B (en) Application of Anti-Nerve Growth Factor Antibody Antagonist in Preparation of Medicine for Postoperative Pain
CN1878794B (en) NGF antagonist and opioid analgesic use in pain treatment
EP3372614B1 (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1594441B1 (en) Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
JP2006517524A5 (en)
WO2005000194A2 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
MXPA02009654A (en) Use of ngf antagonists for the prevention or treatment of chronic visceral pain.
CN101023099A (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
CN118891281A (en) Endosensory modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001254746

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2404117

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009654

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001927818

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 521825

Country of ref document: NZ

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 575999

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10269285

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001927818

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001927818

Country of ref document: EP